Mirum Pharmaceuticals Inc. (MIRM)
MIRM trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price · October 14, 2026
$79.62
-7.48% on the day
Market cap
$5.2B
Mid cap
Revenue · 2025
$521.3M
+54.7% on 2024
Net income · 2025
-$23.4M
-4.5% net margin
Price, change, market cap, sector and industry: Nasdaq stock screener, as of October 14, 2026. Revenue: SEC XBRL frames, calendar 2025.
Profile
| Field | Value |
|---|---|
| Ticker | MIRM on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Country | United States |
| IPO year | 2019 |
| SEC CIK | 0001759425 |
| SEC industry code | Pharmaceutical Preparations |
| Incorporated in | DE |
Financials · 2025
| Line | Value |
|---|---|
| Revenue | $521.3M |
| Net income | -$23.4M |
| Operating income | -$22.1M |
| Net margin | -4.5% |
| Operating margin | -4.2% |
| Revenue growth | +54.7% |
| Cash | $296.7M |
| Total assets | $842.8M |
| P/E (computed) | Net income was not positive |
| P/S (computed) | 9.9× |
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | S-3ASR | 2026-02-25 |
| Latest annual report | 10-K | 2026-02-25 |
| Latest quarterly / interim | 10-Q | 2026-08-05 |
| Latest current report | 8-K | 2026-10-13 |
| Latest proxy | DEFA14A | 2026-04-23 |
Source: SEC EDGAR submissions feed, 667 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | -1.6% |
| 1 month | -15.5% |
| 3 months | -32.4% |
| Year to date | +0.5% |
| 1 year | +10.0% |
| From 52-week high | -38.3% |
Source: Yahoo Finance daily closes, last bar 2026-10-14. Computed by Sophia Capital from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: Pharmaceutical Preparations
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| ERAS | Erasca Inc. | $14.78 | -4.40% | $5.2B |
| PTCT | PTC Therapeutics Inc. | $59.92 | -4.77% | $5.0B |
| GRFS | Grifols S.A. | $7.17 | -2.71% | $4.9B |
| TVTX | Travere Therapeutics Inc. | $51.80 | -0.42% | $4.9B |
| COGT | Cogent Biosciences Inc. | $28.09 | -5.67% | $4.9B |
| MANE | Veradermics Incorporated | $116.26 | -5.02% | $4.9B |
| RYTM | Rhythm Pharmaceuticals Inc. | $86.61 | -3.57% | $6.0B |
| LGND | Ligand Pharmaceuticals Incorporated | $303.53 | -2.44% | $6.1B |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier